[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100373321":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":43,"responsibleParty":91,"collaborators":26,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":97,"sex":103,"minAge":104,"maxAge":26,"enrollmentInfo":105,"targetDuration":26,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Aalborg University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral antibiotics","EXPERIMENTAL","Patients will be randomised to oral antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration\u002Fexcision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess",[13],"Drug: Early transition to oral antibiotics",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard treatment","ACTIVE_COMPARATOR","Patients will be randomised to continuation of standard intravenous antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration\u002Fexcision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess",[19],"Drug: Standard treatment of intravenous antibiotics",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Early transition to oral antibiotics","Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Standard treatment of intravenous antibiotics","Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.",[15],[32],{"name":33,"affiliation":5,"role":34},"Jacob Bodilsen, MD","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+45 97663920","jacob.bodilsen@rn.dk",{"name":41,"role":37,"phone":38,"phoneExt":26,"email":42},"Henrik Nielsen, Professor","henrik.nielsen@rn.dk",[44,58,69,80],{"facility":5,"status":45,"city":46,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Aalborg","Denmark","DK",{"type":50,"coordinates":51},"Point",[52,53],9.9187,57.048,{"lat":53,"lon":52},[56],{"name":57,"role":37,"phone":26,"phoneExt":26,"email":26},"Jacob Bodilsen, MD PhD",{"facility":59,"status":45,"city":60,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Aarhus University Hospital","Aarhus",{"type":50,"coordinates":62},[63,64],10.21076,56.15674,{"lat":64,"lon":63},[67],{"name":68,"role":37,"phone":26,"phoneExt":26,"email":26},"Merete Storgaard, MD",{"facility":70,"status":45,"city":71,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Rigshospitalet","Copenhagen",{"type":50,"coordinates":73},[74,75],12.56553,55.67594,{"lat":75,"lon":74},[78],{"name":79,"role":37,"phone":26,"phoneExt":26,"email":26},"Lars H Omland, MD",{"facility":81,"status":45,"city":82,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Odense University Hospital","Odense",{"type":50,"coordinates":84},[85,86],10.38831,55.39594,{"lat":86,"lon":85},[89],{"name":90,"role":37,"phone":26,"phoneExt":26,"email":26},"Lykke Larsen, MD",{"type":92,"investigatorFullName":93,"investigatorTitle":94,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Henrik Nielsen","Professor","100373321","phase-4-partial-oral-antibiotic-treatment-for-bacterial-brain-abscess-100373321",false,"NCT04140903","Partial Oral Antibiotic Treatment for Bacterial Brain Abscess","Partial Oral Antibiotic Treatment for Bacterial Brain Abscess: an Open-label Randomised Non-inferiority Trial","ORAL","Inclusion Criteria:\n\n1. A clinical presentation (e.g. headache, neurological deficit or fever) and cranial imaging (CT or MRI) consistent with brain abscess AND\n2. The physician responsible for the patient decides to treat the patient for bacterial brain abscess AND\n3. Ability to take and absorb oral medications (including by nasogastric tube) AND\n4. To have received relevant antibiotic therapy for bacterial brain abscess for 14 consecutive days before randomisation AND\n5. Expected to be treated with antibiotic therapy for at least another 14 days after time of randomisation AND\n6. No progression in symptom intensity or occurrence of new-onset neurological symptoms (excluding seizures) within five days before time of randomisation.\n\nExclusion Criteria (patients fulfilling either criteria):\n\n1. Expected substantially reduced compliance with treatment (e.g. IV drug abuse)\n2. Pregnancy (proven by positive urine or plasma human chorionic gonadotropin test in fertile women \\\u003C50 years of age)\n3. Concomitant (empirical) brain abscess treatment for tuberculosis, nocardiosis, Pseudomonas spp., fungi, toxoplasmosis or other CNS parasites\n4. Device related brain abscesses (e.g. deep brain stimulators, ventriculo-peritoneal shunts)\n5. Severe immuno-compromise defined as ongoing need for biological- or chemotherapy, prednisolone \\>20 mg\u002Fday for 14 days or longer, uncontrolled HIV\u002FAIDS, haematological malignancies, and organ transplant recipients\n6. Concomitant or unrelated infections necessitating IV antibiotics beyond seven days of duration after time of randomisation\n7. Previous enrolment into this trial","ALL","18 Years",{"count":106,"type":107},400,"ESTIMATED","INTERVENTIONAL",[110],"PHASE4","The investigators aim to determine if oral antibiotics are clinically acceptable as treatment of brain abscess. Following 2 weeks of standard intravenous antibiotic therapy, half of patients will continue with this treatment for another 4 weeks or longer while the other half will be assigned to oral antibiotics for the remaining duration of treatment.",[113,114],"Brain Abscess","Cerebral Abscess",[9],"2025-01-28",{"date":118,"type":119},"2025-01-30","ACTUAL",{"date":121,"type":119},"2020-11-06",{"date":123,"type":107},"2028-08-31",{"name":93,"class":6},4]